Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs NewcelX Ltd. (NCEL)

Adaptimmune Therapeutics PLC and NewcelX Ltd. are both Biotechnology companies. Adaptimmune Therapeutics PLC and NewcelX Ltd. are of similar size ($15.3M and $14.6M). NewcelX Ltd. has the higher net margin (0.00% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Adaptimmune Therapeutics PLC leads on 5 and NewcelX Ltd. on 5.

Valuation

Metric ADAPY NCEL Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 n/m 9.71
P/B n/m 4.61 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.12 n/m 9.21
Earnings yield (2,166.67%) (61.20%) (33.15%)
Free cash flow yield (2,380.45%) (17.60%) (25.50%)

Profitability

Metric ADAPY NCEL Biotechnology median
Gross margin 94.81% 0.00% 65.16%
Operating margin (427.75%) — 0.00%
Net margin (262.46%) 0.00% 0.00%
Free cash flow margin (288.20%) 0.00% 0.00%
Return on equity (1,349.52%) 0.00% (56.36%)
Return on assets 0.00% 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY NCEL Biotechnology median
Revenue growth (TTM) (53.99%) — 6.02%
EPS growth (last fiscal year) 142.86% 11.18% 30.26%
Revenue growth, 5-year CAGR 8.40% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY NCEL Biotechnology median
Debt to equity (0.36) 0.06 0.00
Current ratio 1.52 0.40 4.72
Net debt to EBITDA 0.47 0.74 0.96

Dividend

Metric ADAPY NCEL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY NCEL Biotechnology median
Market cap 14.55m 15.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack